TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22710579
Drug: Probiotics (Gp‐P,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (Gp‐P, three capsules per day containing 112.5 billion viable lyophilized bacteria per capsule)
Study: 22710579
Drug: No therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No therapy (Gp‐N)
Study: 22710579
Drug: Lactulose (Gp‐L)
Normalized name: Lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lactulose (Gp‐L) vs Probiotics (Gp‐P)
Study: 22710579
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (Gp‐L, Gp‐P, Gp‐N)
Study: 18706417
Drug: Ustekinumab (subcutaneous)
Normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ustekinumab (subcutaneous)
Study: 18706417
Drug: Ustekinumab (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab (subcutaneous and intravenous)
Study: 12698115
Drug: Infliximab (Remicade
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (Remicade 3 mg/kg) intravenously over 2 hours
Study: 1647955
Drug: Pharmacokinetically adjusted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacokinetically adjusted doses of metoclopramide
Study: 1647955
Drug: Standard doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard doses of metoclopramide adjusted to body weight
Study: 6420904
Drug: Inhalation anaesthetic
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation anaesthetic technique (Group A)
Study: 6420904
Drug: Ketamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine infusion technique (Group B)
Study: 26681680
Drug: S-1 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 plus oral leucovorin (LV) at 40, 50, or 60 mg according to body surface area plus LV 25 mg, both given orally twice daily for 1 week, repeated every 2 weeks (SL group)
Study: 26681680
Drug: S-1 monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 monotherapy at the same dose as the SL group for 4 weeks, repeated every 6 weeks (S-1 group)
Study: 26681680
Drug: S-1 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 plus oral leucovorin (LV)
Study: 15790675
Drug: Propacetamol 2
Normalized name: 1,2,3-PROPANETRIOL, 2-(4-AMINOBENZOATE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propacetamol 2 g (i.v. acetaminophen 1 g formulation) administered as a 2-min bolus injection (n=50)
Study: 15790675
Drug: Propacetamol 2
Normalized name: 1,2,3-PROPANETRIOL, 2-(4-AMINOBENZOATE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propacetamol 2 g (i.v. acetaminophen 1 g formulation) administered as a 15-min infusion (n=50)
Study: 15790675
Drug: Oral acetaminophen
Normalized name: acetaminophen Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral acetaminophen 1 g (n=50)
Study: 12213864
Drug: Thyroid hormone
Normalized name: Thyroid hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroid hormone suppressive therapy for longer than 6 months
Study: 9140241
Drug: AHA-recommended technique
Normalized name: AHA
DrugBank: Acetohydroxamic acid (DB00551)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AHA-recommended technique (apex-to-anterior electrode placement, no smearing of gel between electrodes)
Study: 9140241
Drug: Electrode paddles
Normalized name: Paddle weed
DrugBank: Ecklonia cava (DB19252)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrode paddles adjacent, gel smeared between electrodes
Study: 29847382
Drug: 0.15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg/kg methadone
Study: 29847382
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg methadone
Study: 27080282
Drug: Background volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Background volume of 5 mL/h of 0.2% ropivacaine
Study: 27080282
Drug: Background volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Background volume of 3.2 mL/h of 0.2% ropivacaine
Study: 20216387
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion targeting 0 ng/ml
Study: 20216387
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion targeting 2 ng/ml
Study: 20216387
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion targeting 4 ng/ml
Study: 17373174
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination therapy (TCT) - hydroquinone, tretinoin, and fluocinolone acetonide applied once daily
Study: 17373174
Drug: Hydroquinone alone
Normalized name: Hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroquinone alone applied twice daily
Study: 11250991
Drug: Three cycles
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three cycles of bleomycin, etoposide, and cisplatin (BEP) chemotherapy
Study: 11250991
Drug: Four cycles
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four cycles of bleomycin, etoposide, and cisplatin (BEP) chemotherapy
Study: 11250991
Drug: 5-day schedule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day schedule of BEP chemotherapy
Study: 11250991
Drug: 3-day schedule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day schedule of BEP chemotherapy
Study: 11250991
Drug: Three cycles
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three cycles of BEP chemotherapy
Study: 11250991
Drug: Three-day schedule
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-day schedule of BEP chemotherapy
Study: 30091545
Drug: Surface electromyogram
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surface electromyogram biofeedback therapy (sEMGBF)
Study: 30091545
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (ACE+sEMGBF)
Study: 28832550
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin (BoNT) treatment
Study: 28832550
Drug: BoNT treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: BoNT treatment (after 4-7 weeks and again after 11-15 weeks)
Study: 3510268
Drug: Decongestant-antihistamine mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decongestant-antihistamine mixture (Dimetapp)
Study: 29351861
Drug: GOALS therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: GOALS therapy
Study: 29351861
Drug: GOALS therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: GOALS therapy and Treatment as usual
Study: 23110471
Drug: Olmesartan 40
Normalized name: HCTZ 25/OLMESARTAN 40MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan 40 mg, Amlodipine 10 mg, Hydrochlorothiazide 25 mg
Study: 23110471
Drug: Olmesartan 40
Normalized name: HCTZ 25/OLMESARTAN 40MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan 40 mg, Amlodipine 10 mg
Study: 23110471
Drug: Olmesartan 40
Normalized name: HCTZ 25/OLMESARTAN 40MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan 40 mg, Hydrochlorothiazide 25 mg
Study: 23110471
Drug: Amlodipine 10
Normalized name: amlodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 10 mg, Hydrochlorothiazide 25 mg
Study: 27093744
Drug: Captopril 12.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 12.50 mg
Study: 27093744
Drug: Captopril 25.00
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 25.00 mg
Study: 2317417
Drug: Midazolam (0.01-0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.01-0.2 mg kg-1 h-1)
Study: 28215471
Drug: RP5063 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: RP5063 (all doses combined)
Study: 21883353
Drug: Tobramycin once
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin once daily
Study: 21883353
Drug: Tobramycin three
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin three times daily
Study: 17309949
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy (291 patients in parallel group trials)
Study: 17309949
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy (in crossover trials, 265 patients)
Study: 15152059
Drug: Cardiac-resynchronization therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac-resynchronization therapy with a pacemaker
Study: 15152059
Drug: Cardiac-resynchronization therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac-resynchronization therapy with a pacemaker-defibrillator
Study: 15152059
Drug: Optimal pharmacologic
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal pharmacologic therapy alone
Study: 11382723
Drug: Nematode anticoagulant
Normalized name: Recombinant nematode anticoagulant protein-2
DrugBank: Anpocogin (DB06552)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nematode anticoagulant protein c2 3.5 microgram/kg
Study: 8489989
Drug: Fentanyl subcutaneous
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl subcutaneous infusion (F-SC)
Study: 8489989
Drug: Fentanyl plus
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl plus bupivacaine infusion (F-PLX)
Study: 3114663
Drug: 240 mg
Normalized name: aspirin 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg of crystalline melatonin (aMT) administered orally
Study: 2802036
Drug: Antibiotic mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic mouthwash
Study: 21810106
Drug: 16 sessions
Normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 sessions of psychotherapy combined with pharmacotherapy
Study: 21810106
Drug: 8 sessions
Normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 sessions of psychotherapy combined with pharmacotherapy
Study: 21810106
Drug: Both 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both 8 and 16 sessions of psychotherapy combined with pharmacotherapy
Study: 19537522
Drug: Escitalopram 10
Normalized name: escitalopram 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram 10 mg tablet (test preparation)
Study: 19537522
Drug: Escitalopram 10
Normalized name: escitalopram 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram 10 mg tablet (reference preparation)
Study: 16702182
Drug: Rituximab maintenance
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab maintenance treatment (375 mg/m2, one injection every 2 months for six times)
Study: 16702182
Drug: Observation (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation (control group for maintenance treatment)
Study: 8342318
Drug: 1991‐1992 trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1991‐1992 trivalent split influenza vaccine (A/Singapore/6/86 (H1N1), A/Beijing/353/89 (H3N2), B/Yamagata/16/88)
Study: 3569766
Drug: Cisapride (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (10 mg, q.i.d. for 4 weeks)
Study: 27986357
Drug: Less dilated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less dilated left ventricles (EDVI < 90 mL/m2)
Study: 27986357
Drug: Severely dilated
Normalized name: phenylephrine hydrochloride Ophthalmic Solution [AK-Dilate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Severely dilated left ventricles (EDVI ≥ 90 mL/m2)
Study: 25102205
Drug: Norepinephrine/low volume
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine/low volume group (2 μg/kg per hour norepinephrine + 1 ml/kg per hour initially and 3 ml/kg per hour crystalloid infusion after cystectomy)
Study: 25102205
Drug: Standard crystalloid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard crystalloid infusion group (6 ml/kg per hour throughout surgery)
Study: 25102205
Drug: Standard crystalloid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard crystalloid infusion group
Study: 18971883
Drug: Piracetam (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam (12 g at the beginning of the operation)
Study: 12707726
Drug: FLAG-IDA (fludarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLAG-IDA (fludarabine 30 mg/m(2), AraC 2 g/m(2) for 5 days, idarubicin 10 mg/m(2) for 3 days, G‐CSF 5 micro g/kg from day +6 until neutrophil recovery)
Study: 7494233
Drug: Intra-arterial chemotherapy
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial chemotherapy via two-vessel treatment
Study: 7494233
Drug: Intra-arterial chemotherapy
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial chemotherapy via one-vessel treatment
Study: 7494233
Drug: Intra-arterial chemotherapy
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial chemotherapy via middle-cerebral artery treatment
Study: 7494233
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group in the BTCG phase III trial of intra-arterial chemotherapy
Study: 1788749
Drug: i.v. infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. infusion of 40 micrograms PGE1 in 125 ml saline over 60 min
Study: 1788749
Drug: i.a. infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.a. infusion of 10 micrograms PGE1 in 25 ml saline over 30 min
Study: 6756705
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II infusion (5, 10, and 20 ng/kg/min)
Study: 6756705
Drug: Control infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control infusions (placebo)
Study: 29482649
Drug: Paclitaxel plus
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel plus 5-fluorouracil (TF) concurrent with radiotherapy (5-fluorouracil 300 mg/m2 continuous infusion for 96 h plus paclitaxel 50 mg/m2 on day 1 for 5 weeks) followed by consolidation chemotherapy (5-fluorouracil 1800 mg/m2 continuous infusion for 72 h plus paclitaxel 175 mg/m2 on day 1 for 2 cycles)
Study: 29482649
Drug: Cisplatin plus
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin plus 5-fluorouracil (PF) concurrent with radiotherapy (cisplatin 25 mg/m2/d on days 1-3 plus 5-fluorouracil 1800 mg/m2 continuous infusion for 72 h for 2 cycles) followed by consolidation chemotherapy for 2 cycles
Study: 22374842
Drug: Flour inhalation
Normalized name: Flours
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flour inhalation challenge
Study: 22374842
Drug: Control inhalation
Normalized name: Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control inhalation challenge
Study: 21186929
Drug: Buprenorphine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine treatment combined with contingency management for up to 12 weeks
Study: 15703367
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg dexloxiglumide (3 times a day on days 17-20, followed by a single dose on day 21)
Study: 11907926
Drug: Various treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatments for menopause (specific treatments not detailed)
Study: 7665807
Drug: Fluoxetine continuation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine continuation therapy
Study: 2468920
Drug: Verapamil (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (80 mg b.i.d.)
Study: 2468920
Drug: Xamoterol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xamoterol (200 mg b.i.d.)
Study: 792358
Drug: Amikacin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amikacin (150 or 200 mg every hr)
Study: 792358
Drug: Gentamicin (60-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin (60-80 mg every 8 hr)
Study: 24201232
Drug: Risperidone plus
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone plus amantadine (100 mg/d for patients <30 kg or 150 mg/d for patients >30 kg)
Study: 19892078
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (Seeking Safety; SS) plus treatment-as-usual (TAU)
Study: 19892078
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (Seeking Safety; SS)
Study: 9236587
Drug: Amoxicillin-clavulanate for
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanate for 14 days
Study: 9236587
Drug: Amoxicillin-clavulanate for
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanate for 28 days
Study: 2677260
Drug: 5‐fluorouracil (5‐FU),
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐fluorouracil (5‐FU), 600 mg/m2/week for 6 weeks (arm A)
Study: 2677260
Drug: 5‐FU +
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐FU + folinic acid (FA), 200 mg/m2/week for 6 weeks (arm B)
Study: 2677260
Drug: 5‐FU, 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐FU, 600 mg/m2/week for 6 weeks (arm A)
Study: 2677260
Drug: 5‐FU +
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐FU + FA, 200 mg/m2/week for 6 weeks (arm B)
Study: 31830535
Drug: Video game-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Video game-based occupational therapy (VG)
Study: 27841946
Drug: Intensive glycemic
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive glycemic control (BG: 100‐140 mg/dL)
Study: 27841946
Drug: Conservative glycemic
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative glycemic control (BG: 141‐180 mg/dL)
Study: 24197754
Drug: Sham group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham group received the same treatment with 1 Hz (n=15).
Study: 12638032
Drug: Phytosterol-enriched spread
Normalized name: phytosterols
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytosterol-enriched spread (2 x 10 g daily)
Study: 2102123
Drug: Controlled clinical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled clinical trial (medical treatment)
Study: 30641691
Drug: Glimepiride 2
Normalized name: glimepiride 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride 2 mg twice daily + l-carnitine 1 g twice daily
Study: 30641691
Drug: Glimepiride 2
Normalized name: glimepiride 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride 2 mg twice daily
Study: 21866652
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Chinese medicine and chemotherapy
Study: 3311432
Drug: Midazolam (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (12.5 mg) with ketamine (250 mg)
Study: 3311432
Drug: Diazepam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (20 mg) with ketamine (250 mg)
Study: 29914924
Drug: Oral cephalexin
Normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cephalexin 500 mg four times daily
Study: 29914924
Drug: Intravenous cefazolin
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous cefazolin 2 g daily plus oral probenecid 1 g daily
Study: 26954311
Drug: Apremilast (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apremilast (30 mg twice weekly)
Study: 18414108
Drug: Travoprost ophthalmic
Normalized name: travoprost ophthalmic
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Travoprost ophthalmic solution 0.004% (BAK-free)
Study: 18414108
Drug: Travoprost ophthalmic
Normalized name: travoprost ophthalmic
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Travoprost ophthalmic solution 0.004% (with BAK)
Study: 16828939
Drug: Influenza vaccination
Normalized name: Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine Injection [PedvaxHIB]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza vaccination (2004/2005 influenza vaccine)
Study: 8629722
Drug: Assured treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assured treatment design
Study: 6397333
Drug: Flurbiprofen 200
Normalized name: flurbiprofen 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen 200 mg to 400 mg daily
Study: 6397333
Drug: Piroxicam 20
Normalized name: piroxicam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam 20 mg to 40 mg daily
Study: 11593107
Drug: Irbesartan 150
Normalized name: irbesartan 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan 150 mg once daily
Study: 11593107
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg b.i.d.
Study: 9704709
Drug: Filgrastim 5
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Filgrastim 5 microg/kg plus SCF (doses of 5, 10, 15, and 20 microg/kg)
Study: 7989631
Drug: Hypnosis before
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypnosis before injection
Study: 2722725
Drug: Cefmetazole (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefmetazole (2 g single dose administered IV within 90 min of operation)
Study: 2722725
Drug: Cefoxitin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin (2 g single dose preoperative and two additional doses at 6 h intervals post-surgery)
Study: 26501700
Drug: GLN-supplemented parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLN-supplemented parenteral nutrition (GLN-PN)
Study: 26501700
Drug: Standard GLN-free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard GLN-free parenteral nutrition (STD-PN)
Study: 20862932
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment at Renying (ST 9), Fengfu (GV 16), Baihui (GV 20)
Study: 20862932
Drug: Shenmai injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenmai injection combined with 250 mL 5% Glucose injection
Study: 10370789
Drug: Platinum drug
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum drug treatment